CRISPR THERAPEUTICS AG Stock-Based Compensation
CRISPR THERAPEUTICS AG (CRSP) reported Stock-Based Compensation of $33.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-03
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $17.32M, a 1.65% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $16.32M, a 19.24% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $18.08M, a 17.64% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $16.60M, a 22.93% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for fiscal 2025 was $72.50M, a 16.25% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for fiscal 2024 was $86.57M, a 6.84% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for fiscal 2023 was $81.03M, a 17.27% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based payment arrangement, noncash expense for fiscal 2022 was $97.95M, a 4.34% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $17.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $33.64M 10-Q · filed 2026-08-03 | $51.72M derived: sum of 3 quarters · filed 2026-08-03 | $68.32M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $16.32M 10-Q · filed 2026-05-04 | $34.40M derived: sum of 2 quarters · filed 2026-05-04 | $51.00M derived: sum of 3 quarters · filed 2026-05-04 | $68.61M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $18.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $34.68M derived: sum of 2 quarters · filed 2026-02-12 | $52.29M derived: sum of 3 quarters · filed 2026-08-03 | $72.50M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $16.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $34.21M derived: sum of 2 quarters · filed 2026-08-03 | $54.42M 10-Q · filed 2025-11-10 | $76.37M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $17.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $37.82M 10-Q · filed 2026-08-03 | $59.77M derived: sum of 3 quarters · filed 2026-08-03 | $81.31M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $20.21M 10-Q · filed 2026-05-04 | $42.16M derived: sum of 2 quarters · filed 2026-05-04 | $63.70M derived: sum of 3 quarters · filed 2026-05-04 | $87.37M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $21.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $43.49M derived: sum of 2 quarters · filed 2026-02-12 | $67.16M derived: sum of 3 quarters · filed 2026-02-12 | $86.57M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $21.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $45.22M derived: sum of 2 quarters · filed 2025-11-10 | $64.62M 10-Q · filed 2025-11-10 | $83.04M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-06-30 | $23.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $43.08M 10-Q · filed 2025-08-04 | $61.50M derived: sum of 3 quarters · filed 2026-02-12 | $81.47M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | $19.41M 10-Q · filed 2025-05-06 | $37.83M derived: sum of 2 quarters · filed 2026-02-12 | $57.79M derived: sum of 3 quarters · filed 2026-02-12 | $79.56M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | $18.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $38.39M derived: sum of 2 quarters · filed 2026-02-12 | $60.15M derived: sum of 3 quarters · filed 2026-02-12 | $81.03M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $19.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $41.73M derived: sum of 2 quarters · filed 2024-11-05 | $62.61M 10-Q · filed 2024-11-05 | $85.41M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2023-06-30 | $21.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $42.64M 10-Q · filed 2024-08-05 | $65.44M derived: sum of 3 quarters · filed 2025-02-11 | $89.99M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2023-03-31 | $20.88M 10-Q · filed 2024-05-08 | $43.68M derived: sum of 2 quarters · filed 2025-02-11 | $68.22M derived: sum of 3 quarters · filed 2025-02-11 | $93.08M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2022-12-31 | $22.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $47.35M derived: sum of 2 quarters · filed 2025-02-11 | $72.20M derived: sum of 3 quarters · filed 2025-02-11 | $97.95M 10-K · filed 2025-02-11 | |
| 2022-09-30 | $24.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $49.40M derived: sum of 2 quarters · filed 2023-11-06 | $75.14M 10-Q · filed 2023-11-06 | $100.91M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | $24.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $50.60M 10-Q · filed 2023-08-07 | $76.36M derived: sum of 3 quarters · filed 2024-02-21 | $102.56M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | $25.75M 10-Q · filed 2022-05-09 | $51.51M derived: sum of 2 quarters · filed 2024-02-21 | $77.71M derived: sum of 3 quarters · filed 2024-02-21 | $106.04M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | $25.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $51.97M derived: sum of 2 quarters · filed 2024-02-21 | $80.30M derived: sum of 3 quarters · filed 2024-02-21 | $102.39M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $26.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $54.53M derived: sum of 2 quarters · filed 2022-11-01 | $76.62M 10-Q · filed 2022-11-01 | $95.55M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $28.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $50.42M 10-Q · filed 2022-08-08 | $69.35M derived: sum of 3 quarters · filed 2023-02-21 | $86.59M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $22.09M 10-Q · filed 2022-05-09 | $41.02M derived: sum of 2 quarters · filed 2023-02-21 | $58.26M derived: sum of 3 quarters · filed 2023-02-21 | $73.96M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | $18.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $36.17M derived: sum of 2 quarters · filed 2023-02-21 | $51.87M derived: sum of 3 quarters · filed 2023-02-21 | $66.02M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $17.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $32.94M derived: sum of 2 quarters · filed 2021-11-03 | $47.09M 10-Q · filed 2021-11-03 | $58.95M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-06-30 | $15.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $29.85M 10-Q · filed 2021-07-29 | $41.70M derived: sum of 3 quarters · filed 2022-02-15 | $53.05M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-03-31 | $14.15M 10-Q · filed 2021-04-27 | $26.01M derived: sum of 2 quarters · filed 2022-02-15 | $37.35M derived: sum of 3 quarters · filed 2022-02-15 | $48.54M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2019-12-31 | $11.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $23.20M derived: sum of 2 quarters · filed 2022-02-15 | $34.39M derived: sum of 3 quarters · filed 2022-02-15 | $44.06M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $11.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $22.53M derived: sum of 2 quarters · filed 2020-10-28 | $32.20M 10-Q · filed 2020-10-28 | $45.23M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-06-30 | $11.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $20.86M 10-Q · filed 2020-07-27 | $33.88M derived: sum of 3 quarters · filed 2021-02-16 | $41.94M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-03-31 | $9.67M 10-Q · filed 2020-04-28 | $22.70M derived: sum of 2 quarters · filed 2021-02-16 | $30.75M derived: sum of 3 quarters · filed 2021-02-16 | $39.07M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2018-12-31 | $13.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $21.08M derived: sum of 2 quarters · filed 2021-02-16 | $29.40M derived: sum of 3 quarters · filed 2021-02-16 | $34.98M 10-K · filed 2021-02-16 | |
| 2018-09-30 | $8.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $16.38M derived: sum of 2 quarters · filed 2019-10-28 | $21.96M 10-Q · filed 2019-10-28 | $28.94M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-06-30 | $8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $13.91M 10-Q · filed 2019-07-29 | $20.89M derived: sum of 3 quarters · filed 2020-02-12 | $25.75M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-03-31 | $5.58M 10-Q · filed 2019-04-29 | $12.56M derived: sum of 2 quarters · filed 2020-02-12 | $17.43M derived: sum of 3 quarters · filed 2020-02-12 | $21.16M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2017-12-31 | $6.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $11.85M derived: sum of 2 quarters · filed 2020-02-12 | $15.57M derived: sum of 3 quarters · filed 2020-02-12 | $18.87M 10-K · filed 2020-02-12 | |
| 2017-09-30 | $4.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $8.59M derived: sum of 2 quarters · filed 2018-11-07 | $11.89M 10-Q · filed 2018-11-07 | $15.92M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $7.03M 10-Q · filed 2018-08-07 | $11.05M derived: sum of 3 quarters · filed 2019-02-25 | $13.35M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-03-31 | $3.30M 10-Q · filed 2018-05-08 | $3.75M 10-Q · filed 2017-05-11 | $7.33M derived: sum of 2 quarters · filed 2019-02-25 | $9.62M derived: sum of 3 quarters · filed 2019-02-25 | $13.12M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $6.32M derived: sum of 2 quarters · filed 2019-02-25 | $9.82M derived: sum of 3 quarters · filed 2019-02-25 | $10.84M 10-K · filed 2019-02-25 | |
| 2016-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $5.79M derived: sum of 2 quarters · filed 2017-11-08 | $6.82M 10-Q · filed 2017-11-08 | $7.99M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $4.52M 10-Q · filed 2017-08-10 | $5.70M derived: sum of 3 quarters · filed 2018-03-08 | ||
| 2016-03-31 | $1.02M 10-Q · filed 2017-05-11 | $2.20M derived: sum of 2 quarters · filed 2018-03-08 | |||
| 2015-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $3.68M 10-K · filed 2018-03-08 | |||
| 2015-09-30 | $2.51M 10-Q · filed 2016-11-22 | ||||
| 2014-12-31 | $695.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |